Diocese, City of El Paso to host 2 measles vaccine events
EL PASO, Texas (KTSM) — The Diocese of El Paso, along with the City of El Paso Department of Public Health, will host two free measles vaccine events on Sunday, May 18.
The event will be from 8 a.m. to noon on May 18 at Queen of Peace Catholic Church, at 1551 Belvidere St., and at St. Stephen Deacon and Martyr, at 1700 George Dieter.
According to the news release by the Diocese, the events are free to the public with no appointment or insurance needed.
People interested in attending the measles vaccine event should bring their shot record if available, according to the Diocese.
The news release said public health officials recommend the measles vaccine to prevent further spread of the disease. Adults under 68 years of age who do not have a record of receiving the vaccine are strongly encouraged to get vaccinated. However, pregnant women and individuals with compromised immune systems should not receive the vaccine.
'Measles is a highly contagious virus that can spread rapidly, particularly among unvaccinated individuals. The measles vaccine is highly effective, with two doses providing approximately 97 percent protection. Although rare, vaccinated individuals may still contract the virus, but they are far less likely to experience severe symptoms or transmit it to others,' the news release read.
Common symptoms of measles include:
Fever, cough, runny nose, and red eyes.
Rash that begins on the face and spreads downward.
Infected individuals are contagious from four days before to four days after the rash appears (Day 0 is the day the rash appears).
Those at risk of contracting measles include:
Unvaccinated individuals.
Recent travelers to areas with ongoing measles outbreaks.
Immunocompromised individuals, including pregnant women, people with HIV, and those undergoing chemotherapy or other immunosuppressive treatments.
Measles can spread through coughing and sneezing and could linger in the air for up to two hours after an infected person has left the area, the news release said.
For more information on measles symptoms, vaccination and potential exposure, you can contact the City of El Paso's Measles Hotline at (915) 212-HELP (4357), call 211 or visit EPHealth.com under the vaccination and immunization tab.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
A northern Arizona county is reporting 4 measles cases, the state's first in 2025
Health officials in Navajo County in northern Arizona say they've confirmed four measles cases, which are the first cases of the highly contagious respiratory virus in Arizona in 2025. The announcement from the Navajo County Public Health Services District June 9 came amid a national surge of measles, with 1,168 cases reported to the U.S. Centers for Disease Control as of June 6, which is more than four times the number reported during all of 2024. Compounding the threat for Arizonans are recent cases in five neighboring states: California, Colorado, New Mexico, Texas and Utah. The four cases in Navajo County involve people who were not vaccinated against measles. The four were infected from a single source and have a recent history of international travel, health district officials say. Public health officials are trying to identify locations where exposure may have happened and are in the process of identifying people who may have been exposed, the Navajo County health district said in a written statement. Officials estimate the "potential exposure" dates were between May 17 and May 28 and said anyone who may have been exposed should monitor for symptoms for 21 days after exposure. Symptoms include a high fever of more than 101 degrees Fahrenheit, a cough, runny nose, red or watery eyes and a rash beginning at the head and spreading downward A measles outbreak that began earlier this year in Texas killed two unvaccinated school-age children, resulted in 94 hospitalizations and totaled 742 cases overall. In a related outbreak, New Mexico health officials as of June 3 reported 81 measles cases and the death of one adult who tested positive for measles. Arizona is particularly vulnerable to a measles outbreak because community protection has been waning as an increasing number of parents and guardians are choosing not to vaccinate their children with the Measles, Mumps and Rubella vaccine, known as MMR. There likely are several reasons for the decline, including problems accessing the vaccine, vaccine skepticism and a lack of scientifically accurate education about the risks and benefits of immunization against vaccine-preventable diseases such as measles. Measles can affect people of any age and cause an array of complications, including deafness, blindness and brain inflammation, in addition to death. Two doses of the MMR vaccine are 97% effective in protecting against measles infection, evidence shows. Reach health care reporter Stephanie Innes at or follow her on X: @stephanieinnes. This article originally appeared on Arizona Republic: Arizona confirms 4 measles cases amid a national surge
CBS News
an hour ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
Medscape
2 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
